|
Synonyms: LA480 | LY-2875358 | LY2875358
Compound class:
Antibody
Comment: Emibetuzumab is an investigatonal monoclonal antibody designed as a potential treatment for advanced or metastatic solid tumors.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Bioactivity Comments |
| Peptide sequence alignment suggests that emibetuzumab is antibody C8-H241 in patent US8217148 [1]. The binding data mapped to this antibody is derived from this patent. |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
